Data for SemBioSys' insulin to be presented at the American Diabetes Association's 69th Scientific Sessions

    CALGARY, June 5 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), specializing
in the manufacture of high-value proteins and oils in plant seeds, today
announced that it will present the recent results of the Phase I/II study with
its biosimilar human insulin in a late-breaking scientific poster at the
American Diabetes Association's (ADA) 69th Scientific Sessions in New Orleans.
The poster presentation will take place at the Morial Convention Center Poster
Hall E on Sunday, June 7th and is entitled: "Analytical Characterization,
Safety and Clinical Bioequivalence of Recombinant Human Insulin from
Transgenic Plants," by Joseph Boothe and colleagues. The abstract for the
presentation is available via the ADA website at
    The poster presentation details the clinical trial results of SemBioSys'
first "in-man" clinical study of SBS-1000, a recombinant human insulin
manufactured using the Company's proprietary platform, which allows for highly
scalable, low cost production. The trial demonstrated that SBS-1000 was
bioequivalent to Eli Lilly's Humulin(R) R, a widely-used human insulin in
North America, with the expected safety profile. Additionally, SBS-1000 in
humans showed pharmacokinetics and pharmacodynamics indistinguishable from
Humulin(R) R and was well tolerated at pharmacologically active dosages.
SemBioSys plans to publish the complete clinical trial results in a scientific
journal in the near future.

    About SemBioSys

    Calgary, Alberta-based SemBioSys is a world leader in manufacturing
high-value proteins and oils in plant seeds. With its unique, proprietary
platform, SemBioSys provides partners with product enablement, exceptionally
low cost and unprecedented scalability. The Company applies this platform with
high selectivity to opportunities where it has a unique competitive advantage.
Since its inception, SemBioSys has produced more than 50 non-native proteins
and oils using its patented seed technology, demonstrating applicability
across a broad range of industries such as pharmaceuticals, personal care and
industrial products. The Company's current pharmaceutical development programs
include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo
AIMilano, a next-generation cardiovascular therapy. SemBioSys is listed on the
Toronto Stock Exchange under the ticker SBS. More information is available at

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable securities laws. Forward-looking
statements reflect the Company's current expectation and assumptions, and are
subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated. These forward-looking statements
involve risks and uncertainties including, but not limited to, changing market
conditions and market size, the acceptance of an IND by the FDA in respect of
clinical studies, the submission of a CTA to the appropriate European
authorities, the successful initiation and timely and successful completion of
clinical studies, the fact that Apo AIMilano is currently a development stage
drug, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time-to-time in the
Company's ongoing filings with the Canadian securities regulatory authorities
which filings can be found at Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. The Company undertakes no obligation to publicly
update or revise any forward-looking statements either as a result of new
information, future events or otherwise, except as required by applicable
Canadian securities laws.

For further information:

For further information: SemBioSys Genetics Inc., Abby Garfunkel,
Investor Relations, Phone: (403) 717-4185, Email:;
The Trout Group, Christine Labaree, Managing Director, Phone: (617) 583-1307,
E-mail:; The Equicom Group Inc., Ross Marshall, Vice
President, Phone: (416) 815-0700 ext. 238, E-mail:

Organization Profile

SemBioSys Genetics Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890